source
- ArriVent's lead lung cancer drug firmonertinib fails Phase 3 trial, shares plungeArriVent BioPharma announced that its flagship EGFR inhibitor, firmonertinib, did not meet primary endpoints in a late-stage Phase 3 study for lung cancer. The trial results were released on Octobe…
- Compliance worries keep AI adoption in drug manufacturing low, survey findsA new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…